These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 11217236)
1. [Recommendations for the control of cholesterolemia in Spain]. Villar Alvarez F; Mata López P; Plaza Pérez I; Pérez Jiménez F; Maiques Galán A; Casasnovas Lenguas JA; Banegas Banegas JR; Abadal LT; Rodríguez Artalejo F; Gil López E Rev Esp Salud Publica; 2000; 74(5-6):457-74. PubMed ID: 11217236 [TBL] [Abstract][Full Text] [Related]
2. [Cholesterolemia control in Spain, 2000. A tool for cardiovascular disease prevention. Ministry of Health and Consumption, Spanish Society of Cardiology and Spanish Society of Arteriosclerosis]. Rev Esp Salud Publica; 2000; 74(3):215-53. PubMed ID: 10918811 [TBL] [Abstract][Full Text] [Related]
3. [Cardiovascular risk factors and prevention in women: similarities and differences]. Sclavo M Ital Heart J Suppl; 2001 Feb; 2(2):125-41. PubMed ID: 11255880 [TBL] [Abstract][Full Text] [Related]
4. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ; Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):e149-61. PubMed ID: 15297292 [TBL] [Abstract][Full Text] [Related]
5. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ; J Am Coll Cardiol; 2004 Aug; 44(3):720-32. PubMed ID: 15358046 [TBL] [Abstract][Full Text] [Related]
6. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment]. Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737 [TBL] [Abstract][Full Text] [Related]
7. [Individualized cardiovascular prevention: when and how far should it go?]. Guize L Ann Cardiol Angeiol (Paris); 1998 Nov; 47(9):617-25. PubMed ID: 9864557 [TBL] [Abstract][Full Text] [Related]
8. [The best of epidemiology and cardiovascular prevention in 2006]. Thomas D; Collet JP; Cottin Y; Cournot M; Ducimetière P; Ferrières J; Paillard F; Valensi P; Zeller M; Cambou JP Arch Mal Coeur Vaiss; 2007 Jan; 100 Spec No 1():57-64. PubMed ID: 17405566 [TBL] [Abstract][Full Text] [Related]
9. [Control of cholesterolemia in Spain, 2000. A tool for cardiovascular prevention]. Plaza Pérez I; Villar Alvarez F; Mata López P; Pérez Jiménez F; Maiquez Galán A; Casasnovas Lenguas JA; Banegas Banegas JR; Tomás Abadal L; Rodríguez Artalejo F; Gil López E Rev Esp Cardiol; 2000 Jun; 53(6):815-37. PubMed ID: 10944975 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of atorvastatin in achieving National Cholesterol Education Program low-density lipoprotein targets in women with severe dyslipidemia and cardiovascular disease or risk factors for cardiovascular disease: The Women's Atorvastatin Trial on Cholesterol (WATCH). McPherson R; Angus C; Murray P; Genest J; Am Heart J; 2001 Jun; 141(6):949-56. PubMed ID: 11376309 [TBL] [Abstract][Full Text] [Related]
11. [Type 2 diabetes and cardiovascular risk: lessons from therapeutic trials]. Lièvre M Rev Prat; 2001 Oct; 51(16):1793-9. PubMed ID: 11795124 [TBL] [Abstract][Full Text] [Related]
13. [Cardiovascular risk in hemodialysis in Spain: prevalence, management and target results (MAR study)]. Portolés J; López-Gómez JM; Aljama P Nefrologia; 2005; 25(3):297-306. PubMed ID: 16053011 [TBL] [Abstract][Full Text] [Related]
14. Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk. Velussi M Nutr Metab Cardiovasc Dis; 2002 Feb; 12(1):29-35. PubMed ID: 12125227 [TBL] [Abstract][Full Text] [Related]
15. [Association between clustering of cardiovascular risk factors and the risk of cardiovascular disease]. Baena Díez JM; Alvarez Pérez B; Piñol Forcadell P; Martín Peñacoba R; Nicolau Sabaté M; Altès Boronat A Rev Esp Salud Publica; 2002; 76(1):7-15. PubMed ID: 11905401 [TBL] [Abstract][Full Text] [Related]
16. [The PreFord Study. A prospective cohort study to evaluate the risk of a cardiovascular event (overall-collective) as well as a prospective, randomized, controlled, multicentre clinical intervention study (high-risk-collective) on primary prevention of cardiovascular diseases in the Ford Motor Company employees in Germany]. Gysan DB; Latsch J; Bjarnason-Wehrens B; Albus C; Falkowski G; Herold G; Mey E; Heinzler R; Montiel G; Schneider CA; Stützer H; Türk S; Weisbrod M; Predel HG Z Kardiol; 2004 Feb; 93(2):131-6. PubMed ID: 14963679 [TBL] [Abstract][Full Text] [Related]
18. Risk factors of Hong Kong Chinese patients with coronary heart disease. Chair SY; Lee SF; Lopez V; Ling EM J Clin Nurs; 2007 Jul; 16(7):1278-84. PubMed ID: 17584346 [TBL] [Abstract][Full Text] [Related]
19. Vascular risk management through nurse-led self-management programs. Sol BG; van der Bijl JJ; Banga JD; Visseren FL J Vasc Nurs; 2005 Mar; 23(1):20-4. PubMed ID: 15741961 [TBL] [Abstract][Full Text] [Related]
20. Siblings of myocardial infarction patients are overlooked in primary prevention of cardiovascular disease. Hengstenberg C; Holmer SR; Mayer B; Engel S; Schneider A; Löwel H; Riegger GA; Schunkert H Eur Heart J; 2001 Jun; 22(11):926-33. PubMed ID: 11428816 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]